Primary Breast Lymphoma in the United States: 1975–2013

Thomas, Alexandra; Link, Brian K.; Altekruse, Sean F.; Romitti, Paul A.; Schroeder, Mary C.

doi:10.1093/jnci/djw294

Cited by 70 publications

(94 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary breast lymphoma is a rare subtype of NHL representing an estimated 1% of all NHL and less than 3% of extranodal lymphomas . Its definition was first proposed in 1972 by Wiseman and Liao as a malignant lymphoma involving predominantly the breast with or without ipsilateral locoregional lymph nodes .…”

Section: Introductionmentioning

confidence: 99%

“…By this definition, most primary breast lymphoma patients are classified as stage I or II based on the Ann Arbor Staging System, with the exception of bilateral breast lymphoma, which is considered as stage IV by some investigators . The most common histology is DLBCL, although diverse lymphoma subtypes have been reported …”

Section: Introductionmentioning

confidence: 99%

“…Primary breast lymphoma is a rare subtype of NHL representing an estimated 1% of all NHL and less than 3% of extranodal lymphomas. [1][2][3] Its definition was first proposed in 1972 by Wiseman and Liao as a malignant lymphoma involving predominantly the breast with or without ipsilateral locoregional lymph nodes. 4 By this definition, most primary breast lymphoma patients are classified as stage I or II based on the Ann Arbor Staging System, with the exception of bilateral breast lymphoma, which is considered as stage IV by some investigators.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Song

Sun

et al. 2018

Cancer Science

View full text Add to dashboard Cite

Primary breast diffuse large B‐cell lymphoma (PB‐DLBCL) is a rare subtype of DLBCL with limited data on patterns of failure. This multicenter study aimed to define the optimum treatment strategy and patterns of failure for PB‐DLBCL patients. We retrospectively reviewed data on 108 PB‐DLBCL patients from 21 Chinese medical centers. Only patients with localized disease (involvement of breast and localized lymph nodes) were included. After a median follow‐up of 3.2 years, 32% of patients developed progression or relapse. A continuous pattern of relapse was observed, characterized by frequent late relapses in the contralateral breast and central nervous system (CNS). Although rituximab significantly reduced the overall cumulative risk of progression or relapse (5‐year cumulative risk 57% vs 24%, P = .029), it had limited effect on the reduction of breast relapse (P = .46). Consolidative radiotherapy significantly decreased the risk of breast relapse, even in the subgroup of patients treated with rituximab (5‐year cumulative risk 21.2% vs 0%, P = .012). A continuous risk of CNS progression or relapse up to 8.2 years from diagnosis was observed (10‐year cumulative risk 28.3%), with a median time to CNS relapse of 3.1 years. Neither rituximab nor prophylactic intrathecal chemotherapy significantly decreased the risk of CNS relapse. In summary, our study indicates that PB‐DLBCL has a continuous pattern of relapse, especially with frequent late relapses in the CNS and contralateral breast. Rituximab and RT confer complementary benefit in the reduction of relapse. However, neither the addition of rituximab nor prophylactic intrathecal chemotherapy could effectively prevent CNS relapse for PB‐DLBCL patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Song

Sun

et al. 2018

Cancer Science

View full text Add to dashboard Cite

show abstract

“…A regional NET was defined as a neoplasm that (1) extended beyond the limits of the organ of origin directly into surrounding organs or tissue, (2) involved regional lymph nodes, or (3) fulfilled both of the aforementioned criteria. Finally, a distant NET was defined as a neoplasm that spread to parts of the body remote from the primary tumor [12]. …”

Section: Methodsmentioning

confidence: 99%

“…Pathologists in the United States typically use the terms “carcinoid tumor” to denote well-differentiated NETs (G1). The term “atypical carcinoid” is frequently used to describe a moderately differentiated carcinoid and is classified as G2 tumor, poorly differentiated tumors are classified as G3 tumors, and anaplastic tumors are classified as G4 tumors [12]. …”

Section: Methodsmentioning

confidence: 99%

Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival

Yang

Pan

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Gastric neuroendocrine tumors (G-NETs) are uncommon neoplasms that can present with or without clinical symptoms. In this study, we evaluated the incidence, prognosis, and temporal trends of G-NETs. Methods: We analyzed all cases of G-NETs registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2014. Incidence was estimated by age and joinpoint analyses. Survival rates were calculated and survival trends over time were evaluated. Results: A total of 3740 eligible patients were enrolled in the study. G-NETs incidence increased from 0.31 per 1 000 000 patients in 1975 to 4.85 in 2014, with an annual percentage changes (APCs) of 8.9% (95% confidence interval [CI] = 7.7% to 10.21%, P < 0.001, t test (29) from 1975 to 2001 and 3.6% from 2002 to 2014 (95% CI= 2.3% to 4.9%, P < 0.001). For cases diagnosed between 1973 and 1982, five-year survival was 62.8% ± 7.0% (Standard error, SE) and increased to 86.7% ± 0.7% for cases diagnosed between 2003 and 2012 (P < 0.001). Years of diagnosis, gender, age at diagnosis, marital status, grade, tumor size, tumor stage, and surgery performed or not were the strongest predictors of worse survival in both univariate and multivariate analysis (P<0.05). Conclusion: G-NETs are uncommon neoplasms but the incidence is growing. Survival has improved in the past decades. Years of diagnosis, gender, age at diagnosis, marital status, grade, tumor size, tumor stage, and surgery status predict survival in patients with G-NETs.

show abstract

Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast

et al. 2018

View full text Add to dashboard Cite

show abstract

Primary Breast Lymphoma in the United States: 1975–2013

Abstract: PBL has increased in incidence over the last four decades and continues to increase for younger women and for some subtypes. The rise in imaging and procedures to the breast might enhance diagnostic sensitivity for PBL. Further study of the etiologies of PBL is needed.

Cited by 70 publications

References 35 publications

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival

Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast

Contact Info

Product

Resources

About